{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:09:37Z","timestamp":1789229377979,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Even in current guideline-directed medical therapy, including recently introduced vasopressin type 2 receptor antagonist tolvaptan, congestion has not been resolved in patients with heart failure. Kampo medicine goreisan has been receiving considerable attention as an additional therapy for patients who are refractory to conventional diuretics therapy, including tolvaptan. However, the impact of goreisan on urine electrolytes remains uncertain. Methods: Patients with congestive heart failure who received goreisan as an add-on therapy to tolvaptan-incorporated medical therapy were prospectively included. The changes in urine parameters during the first 24 h were assessed as a primary concern. Baseline factors associated with an increase in urine sodium excretion were investigated. Results: A total of 21 patients were included. The median age was 81 (77, 86), and 13 (62%) were men. Twenty-four hours after the initiation of goreisan, urine osmolality decreased significantly, urine sodium level remained unchanged, urine potassium and glucose levels decreased significantly, urine urea nitrogen level tended to decrease, and urine volume tended to increase. The fractional excretion of sodium tended to increase. Baseline plasma B-type natriuretic peptide level had a positive correlation with a change in fractional excretion of sodium from baseline to day 1 (r = 0.52, p = 0.015). Conclusions: Goreisan may increase urine volume via aquaretic and natriuretic effects in patients with congestive heart failure receiving tolvaptan-incorporated medical therapy. Goreisan may have the ability to \u201cmodulate\u201d fluid balance depending on congestion status.<\/jats:p>","DOI":"10.3390\/jcm13247523","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T03:14:58Z","timestamp":1733886898000},"page":"7523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trajectory of Urine Parameters by Adding Herbal Kampo Medicine Goreisan to Tolvaptan in Patients with Congestive Heart Failure"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-8290","authenticated-orcid":false,"given":"Kota","family":"Kakeshita","sequence":"first","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hida","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onoda","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Koike","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC State-of-the-Art Review","volume":"75","author":"Felker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","article-title":"Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jjcc.2021.12.011","article-title":"Kampo medicine for the holistic approach to older adults with heart failure","volume":"80","author":"Yaku","year":"2022","journal-title":"J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1253\/circj.CJ-23-0770","article-title":"Use of Japanese herbal Kampo medicine in patients with acute cardiovascular disease\u2014A 12-year nationwide cohort analysis","volume":"88","author":"Isogai","year":"2024","journal-title":"Circ. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2023.02.013","article-title":"Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: A randomized clinical trial","volume":"260","author":"Yaku","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Isogai, T., Morita, K., Okada, A., Michihata, N., Matsui, H., Miyawaki, A., Jo, T., and Yasunaga, H. (2024). Association between complementary use of Goreisan (a Japanese herbal Kampo medicine) and heart failure readmission: A nationwide propensity score-matched study. J. Cardiol.","DOI":"10.1016\/j.jjcc.2024.09.010"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00380-024-02432-3","article-title":"Short-term impact of kampo goreisan in patients with congestive heart failure refractory to tolvaptan-incorporated medical therapy","volume":"39","author":"Hida","year":"2024","journal-title":"Heart Vessel."},{"key":"ref_13","first-page":"145","article-title":"Effect of goreisan on urinary concentrating ability and expression of aquaporin-2 in 5\/6 nephrectomized rats","volume":"30","author":"Jo","year":"2013","journal-title":"J. Trad. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3923\/jms.2011.30.38","article-title":"Effects of Gorei-san: A traditional Japanese kampo medicine, on aquaporin 1, 2, 3, 4, and V2R mRNA expression in rat kidney and forebrain","volume":"11","author":"Kurita","year":"2011","journal-title":"J. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jep.2016.03.030","article-title":"Quantitative evaluation of Oryeongsan and its action on water regulation in renal inner medullary collecting duct cells","volume":"185","author":"Lee","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jep.2012.02.021","article-title":"Oryeongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin-angiotensin-aldosterone system in rats","volume":"141","author":"Ahn","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9159292","DOI":"10.1155\/2022\/9159292","article-title":"Amelioration of hypertension by Oryeongsan through improvements of body fluid and sodium balance: Roles of the renin-angiotensin system and atrial natriuretic peptide system","volume":"2022","author":"Ahn","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101007","DOI":"10.1016\/j.imr.2023.101007","article-title":"Herbal medicine (Oryeongsan) for fluid and sodium balance in renal cortex of spontaneously hypertensive rats","volume":"13","author":"Ahn","year":"2024","journal-title":"Integr. Med. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8844031","DOI":"10.1155\/2020\/8844031","article-title":"Antihypertensive and renal protective effects of Oryeongsan in spontaneously hypertensive rats","volume":"2020","author":"Kang","year":"2020","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:59Z","timestamp":1760115119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":20,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247523"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247523","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}